Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2018-01-15 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen dated January 15, 2018, announcing its participation in the ASCO Gastrointestinal Cancers Symposium. It details the 13 posters and 1 oral presentation that will feature Ipsen's products (Onivyde®, Cabometyx®, Somatuline®, Xermelo®) at the conference happening from January 18-20, 2018. It also mentions a co-organized financial community meeting to discuss the data. This type of announcement, detailing upcoming scientific presentations and data releases at a medical conference, is characteristic of an Investor Presentation (IP) or a general corporate/investor relations update, rather than a formal regulatory filing like a 10-K, ER, or IR. Since it is a detailed announcement intended for investors and the medical community about upcoming data presentations, 'Investor Presentation' (IP) is the most fitting category, although it functions as a corporate announcement about scientific data dissemination.
2018-01-15 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen dated January 15, 2018, announcing data presentations (posters and an oral abstract) at the 2018 ASCO Gastrointestinal Symposium regarding several of their products (Onivyde, Cabometyx, etc.). It details the schedule, abstract numbers, and key findings/authors. This type of announcement, focusing on scientific data presentation at a medical conference, is not a standard regulatory filing like 10-K, ER, or IR. It is an announcement related to investor/scientific communication. Since it is not a formal financial report, a management change, or a specific regulatory filing, and it details scientific/clinical data dissemination, it fits best under Investor Presentation (IP) or potentially Regulatory Filings (RNS) as a general corporate communication. Given the focus on presenting clinical trial data (like the CELESTIAL trial results) to the medical/investor community, 'Investor Presentation' (IP) is the most appropriate fit, as these announcements often precede or accompany investor briefings about the data.
2018-01-15 English
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant executive appointment: Richard Paulson as EVP and CEO of Ipsen North America. This type of announcement, detailing changes in senior leadership, directly corresponds to the definition of 'Board/Management Information'. It is not an earnings release, a full annual report, a proxy statement, or a transcript. Therefore, the appropriate classification is MANG.
2018-01-12 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 98% confidence The document is titled with a personnel announcement: "Ipsen nomme Richard Paulson Vice-Président exécutif et Directeur Général d'Ipsen Amérique du Nord". It details the appointment of a new executive, including his responsibilities, reporting structure, and background. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2018-01-12 French
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 90% confidence The document is titled "Monthly information regarding the total number of voting rights and total number of shares of the Company" and references Article 223-16 of the AMF General Regulations. It provides a table showing the total number of shares and total voting rights as of December 31, 2017. This type of periodic disclosure regarding share capital and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning share structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, although it is a monthly update rather than a major change announcement. However, given the specific nature of reporting voting rights monthly, and lacking a dedicated 'Voting Rights Disclosure' code, 'SHA' is the most appropriate classification related to capital structure changes/status. If a more general regulatory filing code were needed, RNS would apply, but SHA captures the content better.
2018-01-12 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). The content provides a table detailing the total number of shares and total voting rights as of a specific date (December 31, 2017). This type of mandatory periodic disclosure regarding the share capital structure and voting rights is a specific regulatory filing requirement, often related to capital changes or shareholder structure updates. It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with notifications concerning share capital structure or major shareholdings, but since it is a specific, recurring regulatory disclosure about the total number of shares and voting rights, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-standard filing type, or potentially 'SHA' (Share Issue/Capital Change) if the context implies a change, but RNS is safer for mandatory periodic disclosures not covered elsewhere. Given the options, RNS serves as the best fit for mandatory, periodic regulatory updates not covered by the more specific codes like 10-K or ER.
2018-01-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.